Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate–severe traumatic brain injury

Changes in quantitative EEG (qEEG) recordings over a 1-year period and the effects of Cerebrolysin (Cere) on qEEG slowing and cognitive performance were investigated in postacute moderate–severe traumatic brain injury (TBI) patients. Time-related changes in qEEG activity frequency bands (increases o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Neural Transmission 2008-05, Vol.115 (5), p.683-692
Hauptverfasser: Álvarez, X. Antón, Sampedro, Carolina, Figueroa, Jesús, Tellado, Iván, González, Andrés, García-Fantini, Manuel, Cacabelos, Ramón, Muresanu, Dafin, Moessler, Herbert
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Changes in quantitative EEG (qEEG) recordings over a 1-year period and the effects of Cerebrolysin (Cere) on qEEG slowing and cognitive performance were investigated in postacute moderate–severe traumatic brain injury (TBI) patients. Time-related changes in qEEG activity frequency bands (increases of alpha and beta, and reductions of theta and delta relative power) and in qEEG slowing (reduction of EEG power ratio) were statistically significant in patients with a disease progress of less than 2 years at baseline, but not in those patients having a longer disease progress time. Slowing of qEEG activity was also found to be significantly reduced in TBI patients after 1 month of treatment with Cere and 3 months later. Therefore, Cere seems to accelerate the time-related reduction of qEEG slowing occurring in untreated patients. The decrease of qEEG slowing induced by Cere correlated with the improvement of attention and working memory. Results of this exploratory study suggest that Cere might improve the functional recovery after brain injury and encourage the conduction of further controlled clinical trials.
ISSN:0300-9564
1435-1463
DOI:10.1007/s00702-008-0024-9